There are many intractable diseases in the world for which no cure has been found, as well as many difficult-to-cure diseases. Notably, research and development of therapeutic agents for infectious diseases such as malaria, tuberculosis, and NTDs, which are prevalent in developing countries, is not progressing due to unpromising marketability. Furthermore, inadequate medical systems, poverty, and disasters in developing countries prevent them from receiving needed medicines and medical services.
To address these issues of access to healthcare, the Group will leverage its strengths in drug discovery, and work in partnership with NPOs/NGOs, industry groups, and others based on our MISSION of “Creating hope for all facing illness.”

We have created treatment options for intractable diseases such as inflammatory bowel disease and multiple sclerosis.
Providing new options for diseases for which there has been no cure is our MISSION itself. We seek to realize precision medicine for diseases for which unmet medical needs remain, especially in the central nervous system and immunoinflammatory areas. In addition, we will contribute to improving the quality of life of patients and their families by providing solutions based on therapeutic medicine from prevention to prognosis.
For the materiality monitoring indicator, we have designated a new “Development pipeline quantity for rare and intractable diseases,” and have disclosed the pertinent results from fiscal 2021.

Dersimelagon is being developed as a new treatment option for erythropoietic protoporphyria and X-Linked protoporphyria, which causes painful skin symptoms when exposed to sunlight. In 2021, we began clinical trials of Dersimelagon as a treatment for systemic sclerosis, which is a rare disease and characterized by hardening of the skin and internal organs.

Going forward, we will work on research and development to attain our MISSION and contribute to the realization of a healthy and sustainable society by offering a promising option to a large number of patients around the world who are struggling with intractable diseases, as well as to their families.

Controlling infectious diseases that are prevalent in developing countries leads to improved living conditions for people and the overcoming of poverty, creating a virtuous cycle not only in developing countries but throughout the world. As a drug discovery company, we believe that leveraging our strengths in drug discovery is the best way to contribute, and we are conducting research on therapeutic drugs for infectious diseases through the GHIT Fund. We also provide various support through collaborative research efforts with non-profit organizations aimed at creating new antimicrobial medications for use against drug-resistant bacteria, and by paying attention to intellectual property in developing countries and donating to NPOs and NGOs.

The Global Health Innovative Technology Fund (GHIT Fund), is Japan's first public-private partnership to promote the creation of innovative treatment agents for infectious diseases that affect people in developing countries, such as malaria, tuberculosis, and neglected tropical diseases (NTDs). We support the GHIT Fund’s objective of contributing to global health, and financially support the fund.

Meanwhile, with funding from the GHIT Foundation, we are researching with our partners infectious disease treatments that are widespread in developing countries.
In particular, the eradication of malaria and NTDs presented below is listed as one of the 169 targets linked to the 17 goals of the United Nations’ Sustainable Development Goals (SDGs). Improving medical access is also a materiality for our company, so we will continue to actively promote it.

Malaria is one of the three most serious infectious diseases, killing approximately 600,000 people each year. Utilizing funding from the GHIT Fund, we collaborated with MMV (Medicines for Malaria Venture), to start a joint antimalarial drug research in December 2014, which featured a discovery screening program that was succeeded in identifying promising hit compounds. In addition, we promoted joint research and from one of these compounds, we acquired two lead compounds as new anti-malaria drug candidates, and moved to the lead optimization stage in April 2019. Moreover, in October 2023, we acquired funding for further research from GHIT Fund, and with the University of Georgia as an additional partner, are continuing collaborative research to create preclinical candidates.

The Global Health Innovative Technology Fund provides grants for joint research into anti-malarial drugs with novel mechanisms of action conducted by Mitsubishi Tanabe Pharma and a malaria research institution［PDF：333KB］

WHO defines 21 diseases as NTD (Neglected Tropical Diseases) that humanity must control. In September 2019, we launched a collaboration supported by GHIT Fund for a discovery screening program with DNDi (Drugs for Neglected Diseases initiative), which is dedicated to developing drugs for these diseases, and acquired a hit compound for one such neglected disease, Chagas disease. In April 2021, DNDi and we started a Hit to Lead (HL) study for Chagas disease to create lead compounds and succeeded in generating a lead compound with promising efficacy in a preclinical Chagas model. From April 2024, we acquired funding for further research from GHIT Fund and began lead optimization research. Additionally, in fall 2023, Mitsubishi Tanabe Pharma and DNDi were jointly awarded “DNDi 2023 Project of the Year in Pre-Clinical Research” for the results of the joint research.

Every year DNDi offers awards to teams and partners that have achieved significant results in projects conducting preclinical and clinical research. The DNDi Scientific Advisory Committee makes nominations from among more than 40 projects in DNDi’s R&D portfolio, and two of those nominated are selected for awards by Executive Board members from DNDi.

The Global Health Innovative Technology Fund provides grants to Mitsubishi Tanabe Pharma and DNDI for Chagas disease drug discovery［PDF：376KB］

Headquartered in Switzerland, the non-profit Global Antibiotic Research and Development Partnership (‘GARDP”) develops new medications for drug-resistant bacterial infections that pose a grave danger to our health. It was established in 2016 by the World Health Organization (WHO) and DNDi (the Drugs for Neglected Diseases initiative) to ensure that everyone who needs antimicrobial drugs has access to effective, affordable treatment.
In November 2011, Mitsubishi Tanabe Pharma concluded a contract with GARDP to offer its screening compound library with the goal of developing new antimicrobial drugs for use against drug-resistant bacteria. This screening resulted in the successful acquisition of several types of hit compounds, and we are currently evaluating the potential for further joint research. Through these initiatives, we support GARDP efforts to address serious bacterial infections caused by drug-resistant bacteria.

GARDP and Mitsubishi Tanabe Pharma Corporation announce partnership in search for new antibiotics［PDF：177KB］

Mitsubishi Tanabe Pharma Group has established a policy on intellectual property that forms the basis for providing new healthcare opportunities in order to appropriately protect and make effective use of its globally competitive intellectual property. On the other hand, in countries where serious economic problems make access to healthcare difficult, we need to consider enforcing our patent rights. The Group contributes to healthcare access in economically deprived areas around the world. Therefore, as a general rule, we do not enforce our patent rights in the Least Developed Countries (LDCs) stipulated by the United Nations.
Please see “Protection of Intellectual Property Rights” for details.

Please see “Contributions to Medical Care and Welfare” for details about these initiatives.